AJM onlineClinical research studyCardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-α Blockade with Nonbiologic DMARDs
Section snippets
Design and Study Cohort
This study was part of a larger study collaborative (SABER: The Safety Assessment of Biologic Therapy).18 The collaborative study shared limited datasets across institutions to facilitate large-scale comparative effectiveness studies, while maintaining de-identified analytic cohorts.19 The datasets that were combined include the US Medicaid Analytic Extract linked to national US Medicare data for patients with both (so-called “dual eligibles” with Medicare and Medicaid eligibility), the
Results
The study cohort was assembled from 4 databases that provided 139,611 potentially eligible rheumatoid arthritis patients (Figure 1). Among this group, 22,907 patients had used methotrexate and then added or switched to one of the agents of interest: 9964 added or switched to a nbDMARD and 12,943 to a TNF-α blocking agent. After excluding subjects with the highest and lowest 5% of propensity scores, we compared 8656 new users of a nbDMARD with 11,587 new users of a TNF-α blocking agent.
Baseline
Discussion
As greater evidence accumulates for the role of inflammation in atherosclerosis, consideration has been given to the use of immunosuppressive treatment regimens in cardiovascular disease. While statins and aspirin may reduce cardiovascular risk in part through their anti-inflammatory properties,30, 31 targeting cytokines known to be part of cardiovascular disease is an attractive therapeutic option. Because the use of potent immunosuppressive agents is common in a systemic inflammatory
Acknowledgement
This work was supported by the Agency for Healthcare Research and Quality (AHRQ) and the Food and Drug Administration (FDA) US Department of Health and Human Services (DHHS) as part of a grant (No. 1U18 HSO17919-0) administered through the AHRQ CERTs Program. The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by AHRQ, FDA, or DHHS. This work was part of a larger collaborative, the Safety Assessment of Biologic Therapy
References (42)
- et al.
Rheumatoid arthritis
Lancet
(2001) - et al.
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records
Am Heart J
(2004) - et al.
A comparison of death certificate out-of-hospital coronary heart disease death with physician-adjudicated sudden cardiac death
Am J Cardiol
(2005) - et al.
Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III
Value Health
(2009) - et al.
TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure
Pharmacol Ther
(2010) - et al.
Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Am Heart J
(2011) - et al.
Inflammatory markers and onset of cardiovascular events: results from the Health ABC study
Circulation
(2003) - et al.
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction
Circulation
(2000) - et al.
Role of cytokines in rheumatoid arthritis
Annu Rev Immunol
(1996) - et al.
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis
Circulation
(2003)
Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies
Arthritis Rheum
Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis
Arthritis Rheum
Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity
Ann Rheum Dis
Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives
Ann Rheum Dis
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
Arthritis Res Ther
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis
J Rheumatol
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
Ann Rheum Dis
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
Ann Rheum Dis
A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases
Rheumatology (Oxford, England)
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register
Arthritis Rheum
Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis
Arthritis Rheum
Cited by (0)
Funding: This work was supported by the Agency for Healthcare Research and Quality (AHRQ) and the Food and Drug Administration (FDA) US Department of Health and Human Services (DHHS) as part of a grant (No. 1U18 HSO17919-0) administered through the AHRQ CERTs Program.
Conflict of Interest: DHS has received research grants from Abbott, Amgen, and Lilly; has served in unpaid roles on 2 Pfizer trials not related to rheumatoid arthritis; has directed an educational course supported by Bristol Myers Squibb; and serves as a consultant to CORRONA. JRC has received research grants or consulted (or both) with Amgen, Abbott, BMS, Genentech/Roche, Janssen, UCB, and CORRONA. LRH serves as a consultant to CORRONA. JDL has received research grant from Centocor and served as a paid consultant to Amgen and Pfizer.
Authorship: All authors had access to the data and a role in writing the manuscript.